Physician-scientists in the Cancer Center at CHOP have developed a preclinical, potent therapy attached to an antibody that targets a surface protein expressed in most childhood neuroblastomas, effectively killing cancer cells.

Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells.

Neuroblastoma, a pediatric cancer of the developing peripheral nervous system that usually occurs as a solid tumor in a child's chest or abdomen, is the most common cancer in infants, and accounts for more than 10 percent of all childhood cancer deaths. Children with the high-risk form of the disease continue to have a poor prognosis, despite intensive drug therapy.

In cell cultures and animal models of neuroblastoma, the ADC-ALK approach killed neuroblastoma cells, with no discernible toxicity to healthy cells. "The goal of this approach is to harness the presence of ALK to precisely deliver a poison only to the cancer cell, without harming the healthy surrounding cells," said Mossé.

Biochempeg is dedicated to being your most reliable partner to provide a chemical synthesis and high-quality ADC linkers (PEG linkers ). We are committed to promoting the progress of your ADC discovery and development projects.


About us:
Biochempeg Scientific Inc.
Website: https://www.biochempeg.com
Email: [email protected]